NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
- Posted
- June 27, 2023
- Closed
- January 6, 2025
- Award ceiling
- $500,000
- Cost sharing
- No
- Instrument
- Grant
- Assistance listing
- 93.867
- Category
- Health
- Archives
- February 5, 2025
Program funding history
Awards made under Assistance Listing 93.867 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $696.7M
- FY2026 obligated
- $693.8M
- FY2027 (to date) obligated
- $0
- Awards in window
- 3,058
Top recipients: The Johns Hopkins University, The Leland Stanford Junior University, Jaeb Center for Health Research Foundation, Inc., Regents of the University of California, San Francisco, the, University of California, Los Angeles
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase will support research that is in the final states of preclinical development with potential for near-term clinical development. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion R33, PAR-23-205.
Who can apply
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal governments (Federally recognized)
- State governments
- County governments
- For profit organizations other than small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- City or township governments
- Public and State controlled institutions of higher education
- Public housing authorities/Indian housing authorities
- Special district governments
- Private institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Independent school districts
- Small businesses
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
The official record
Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.
View on Grants.gov Full announcement
New to federal funding? How to read an announcement · Who can apply · How grants work
Tell me when this program posts again
This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
- NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)
- NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
- NEI Collaborative Clinical Vision Research (UG1 - Clinical Trial Optional)
- NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing